MAPT and Alzheimer disease: Differentiation among the different neurodegenerative diseases (e. g., Parkinson's disease and Alzheimer's disease) has so far not been possible.6 Recently, molecules have been developed which specifically bind to Aβ and not to α‐synuclein or tau fibrils and potentially enable an early diagnosis of a particular neurodegenerative disease.7 A particularly promising series of compounds is based on the molecule 4,4′‐diaryl‐2,2′‐bithiazole (DABTA).